BrBiotec Brazil launched at BIO 2010, looking for the worldwide market
A total of 22 Brazilian companies and entities linked to biotechnology took part in the BIO International Convention 2010, held on May 3-6 in Chicago, USA, in partnership with the Brazilian Trade and Investment Promotion Agency (Apex-Brazil). At the Convention the BrBiotec Brazil brand was launched, to characterize the country's products at the international level.
The biotechnology market generates around $10 billion/year for the country, with the largest emphasis on the public health and natural environment areas, but the National Biotechnology Policy, established in 2007, estimates that Brazil will be among the five largest worldwide business poles until 2015.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze